Articles

Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne
Tumor Suppression and Cancer Sex Disparity Lab, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne
Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111
Translational Medicine, Bristol-Myers Squibb, Cambridge, MA, USA, (current: io904 LLC)
Oncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne
Department of Haematology, St Vincent’s Hospital, Melbourne, Australia; Faculty of Medicine, The University of Melbourne
Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne
Faculty of Medicine, The University of Melbourne, Australia; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Faculty of Medicine, The University of Melbourne, Australia; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Faculty of Medicine, The University of Melbourne, Australia; Immunology Division, Walter and Eliza Hall Institute, Melbourne, Australia; Institute for Molecular Science, La Trobe University, Bundoora
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Haematologica Early view Jun 30, 2022 https://doi.org/10.3324/haematol.2021.279930